Welcome to our dedicated page for Nutriband SEC filings (Ticker: NTRBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutriband Inc. filings document a transdermal pharmaceutical developer with Nasdaq-listed common stock and warrants. The company's Form 8-K reports cover Regulation FD disclosures on AVERSA product development, an abuse-deterrent fentanyl transdermal system, brand-name and labeling activity, and material communications related to its prescription patch portfolio.
Regulatory filings also describe capital-structure matters for NTRB and NTRBW, including warrant and option exercises, Series A preferred stock issuance, amendments to governing documents, and stockholder meeting results. Other disclosures address subsidiary transaction matters, board and audit-firm votes, securities registered on Nasdaq, and governance actions tied to Nutriband's public-company reporting obligations.
Nutriband Inc. filed an amendment to its annual report for the year ended January 31, 2026 to add a missing exhibit. The company is now including its Policy Relating to Recovery of Erroneously Awarded Compensation, referred to as the executive compensation Clawback Policy, as Exhibit 97.1.
The Clawback Policy was adopted on January 24, 2026 to comply with NASDAQ listing standards and SEC Rule 10D-1 but was omitted from the original 2026 Form 10-K. The amendment states that, aside from reflecting adoption and filing of this policy, it does not modify or update any other disclosures.
Nutriband Inc. filed an amendment to its annual report for the year ended January 31, 2026 to add a missing exhibit. The company is now including its Policy Relating to Recovery of Erroneously Awarded Compensation, referred to as the executive compensation Clawback Policy, as Exhibit 97.1.
The Clawback Policy was adopted on January 24, 2026 to comply with NASDAQ listing standards and SEC Rule 10D-1 but was omitted from the original 2026 Form 10-K. The amendment states that, aside from reflecting adoption and filing of this policy, it does not modify or update any other disclosures.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. reported continued operating losses and liquidity activity for the six months ended July 31, 2025. The company recorded a net loss of $3,416,710 for the six-month period and used $2,650,313 of cash from operations. Total goodwill remained $1,719,535. Inventory was $138,031 (work-in-process $8,061; finished goods $8,042; raw materials $121,477). The company completed an $8,400,000 equity financing on April 19, 2024 and received $5,305,503 from warrant exercises during the six months ended July 31, 2025. A related-party credit line facility of $5,000,000 (originally $2,000,000) is available; advances bear 7% interest and are due March 19, 2026. The company has operating losses since inception and relies on equity sales and debt to fund operations.
Nutriband Inc. reported recent exercises of its outstanding stock options and warrants for the period from February 1 through July 31, 2025. Holders exercised stock options covering 20,055 shares of common stock for a total exercise price of $44,206.
During the same period, holders of the company’s publicly traded warrants (trading under symbol NTRBW) exercised warrants to purchase 47,076 shares of common stock for a total purchase price of $302,699. In addition, private investors exercised warrants to purchase 778,041 shares of common stock, generating a total exercise price of $5,002,804.
Form 8-K highlights
On 5 Aug 2025 Nutriband (Nasdaq: NTRB) completed a stock dividend of 3,008,643 Series A Convertible Preferred shares, issuing one preferred share for every four common shares held as of 25 Jul 2025 (fractions rounded down). The distribution is treated as an unregistered sale under Item 3.02.
Item 5.03 notes that the board, without shareholder vote, amended the Articles of Incorporation on 9 Jul 2025 to create the Series A non-voting preferred class (par $0.001). Authorised shares were first set at 2.79 m and later increased to 10 m via a Certificate of Correction filed 21 Jul 2025.
The preferred shares will convert 1-for-1 into common stock only after FDA approval of AVERSA-based transdermal products. Until conversion eligibility and SEC/Nasdaq registration are complete, the shares are restricted and held by transfer agent Equiniti. Holders may receive dividends declared on either preferred or common stock. Exhibits 3.1D and 3.1E contain the charter amendment and correction.